Abstract
Serum testosterone (T) and dihydrotestosterone (DHT) were measured by a sensitive and reliable radioimmunoassay in 42 normal subjects and 33 age-matched patients with carcinoma of the prostate. The mean +/- s.e. for serum testosterone in normal subjects was 16.74 +/- 0.76nM and the corresponding value for patients with carcinoma was 20.94 +/- 1.48nM. Statistical analysis of the results showed a significant increase in T level in patients with carcinoma of the prostate (P less than 0.01). In contrast, there was no difference in DHT concentration between the two groups, values being 2.43 +/- 0.09 and 2.06 +/- 0.09nM for normal subjects and patients respectively. The means +/- s.e. for T/DHT ratio in controls and patients were 6.8 +/- 0.2 and 12.8 +/- 1.3 respectively. The difference was highly significant (P less than 0.001). The wide range of variation for T in patients with carcinoma would suggest that although mean T is higher in these patients, this measurement alone is of little practical value, whereas T/DHT ratio is a more reliable parameter in evaluating the androgen changes in these patients. The significance of these findings in relation to the aetiology of the disease is discussed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Ghanadian, R., Puah, C. & O'Donoghue, E. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 39, 696–699 (1979). https://doi.org/10.1038/bjc.1979.122
Issue Date:
DOI: https://doi.org/10.1038/bjc.1979.122
This article is cited by
-
EpidemiologÃa del cáncer de próstata
Revista de OncologÃa (2001)
-
Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey
Cancer Causes and Control (1993)
-
Gestagens in the management of prostatic carcinoma
International Urology and Nephrology (1984)